# Treatment Prioritisation and Cost-Effectiveness Analysis for HBV Cure - Real-World Evidence from a Territory-Wide Cohort

> **NCT06627608** · — · NOT_YET_RECRUITING · sponsor: **Chinese University of Hong Kong** · enrollment: 10000 (estimated)

## Conditions studied

- Chronic Hepatitis B

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06627608
- **Lead sponsor:** Chinese University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-11-01
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 10000 (ESTIMATED)
- **Last updated:** 2024-10-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06627608

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06627608, "Treatment Prioritisation and Cost-Effectiveness Analysis for HBV Cure - Real-World Evidence from a Territory-Wide Cohort". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06627608. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*